BioHarvest Sciences Q1 Earnings Call Highlights BioHarvest Sciences logo MarketBeat May 14, 2026 7 min read BHST Key Points Interested in BioHarvest Sciences Inc.? Here are five stocks we like better. BioHarvest Sciences reported first-quarter revenue of $8.5 million, up 8% year over year, and kept its 2026 guidance unchanged for both the D2C and CDMO businesses.
Cash and deposits rose sharply to $20.2 million from $3.4 million a year earlier. The company is reorganizing around a two-business structure: the VINIA direct-to-consumer segment and the CDMO platform. Management said this should improve capital allocation and execution, while also preparing for a new manufacturing facility expected to begin production in 2H 2027.
BioHarvest highlighted CDMO progress in fragrance and saffron, including a $1.2 million stage 2 fragrance contract and completion of saffron stage 1. Management also said it expects more CDMO projects ahead and remains focused on a marketing reset for VINIA to improve customer acquisition efficiency. BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.
The plant cell culture biotechnology company said revenue for the first quarter of 2026 rose 8% year over year to $8.5 million, compared with $7.9 million in the prior-year period. Gross profit increased to $5 million, or 59% of revenue, from $4.6 million, or 58% of revenue, a year earlier. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? Net loss widened to $2.6 million, or $0.11 per basic and diluted share, compared with a net loss of $2.3 million, or $0.13 per basic and diluted share, in the same quarter last year.
Adjusted EBITDA loss, a non-IFRS measure, was $1.2 million, in line with the year-earlier period. Cash and cash equivalents, together with bank deposits, totaled $20.2 million as of March 31, 2026, up from $3.4 million as of March 31, 2025. Company Emphasizes Two-Business Structure → MP Materials Is Quietly Building a Rare Earth Powerhouse Chief Executive Officer Zaki Rakib said BioHarvest is now managing the company through a "two-lens" framework, separating the operating view of its D2C products business from its CDMO services division.
Rakib said the approach is intended to improve performance, capital allocation and execution. Under that framework, the company reported an adjusted EBITDA loss of $904,000 for the CDMO services division and $286,000 for the products division in the first quarter. In the year-ago quarter, those losses were $953,000 and $235,000, respectively.
Extract — continue reading at the source.
